<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> (RGZ), a peroxisome proliferator-activated receptor-gamma (PPAR-gamma), has been shown to provide neuroprotective and anti-inflammatory effects in the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, and traumatic or surgical brain injuries </plain></SENT>
<SENT sid="1" pm="."><plain>However, the effect of delayed post <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> administration of this compound is still unclear </plain></SENT>
<SENT sid="2" pm="."><plain>This study was designed to evaluate the neuroprotective effects of RGZ when first administered at 24 h after the embolic model of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Embolic focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was induced in rats by placing a preformed clot into the middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) </plain></SENT>
<SENT sid="4" pm="."><plain>RGZ (5 mg/kg, intraperitoneally) was injected at 24 and 48 h after <z:chebi fb="70" ids="34342">MCA</z:chebi> embolization </plain></SENT>
<SENT sid="5" pm="."><plain>Neurological deficits were evaluated at 24, 48 and 72 h after <z:hpo ids='HP_0001297'>stroke</z:hpo>, and blood and brain tissues were then collected for differential blood cell counts and assessments of <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and DNA fragmentation, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Compared to the control group, the administration of RGZ, starting 24 h after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 56% (P&lt;0.05) and decreased neurological deficits at 72 h after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> (P&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Also, delayed administration of RGZ prevented <z:mp ids='MP_0000219'>neutrophilia</z:mp> in blood (P&lt;0.005) and significantly decreased DNA fragmentation (P&lt;0.05), 72 h after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, our data demonstrate that treatment with RGZ, starting 24 h after <z:hpo ids='HP_0001297'>stroke</z:hpo>, can reduce ischemic injury, improve neurological outcome, and prevent <z:mp ids='MP_0000219'>neutrophilia</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>These findings may support the idea that RGZ has an extended therapeutic window for the treatment of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, as it targets delayed pathways </plain></SENT>
</text></document>